Results 181 to 190 of about 52,371 (280)

Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma - De Novo Occurrence or Transformation

Turkish Journal of Hematology, 2015
Smeeta Gejendra, Bhawna Jha, Shalini Goel, Tushar Sahni, Pranav Dorwal, Ritesh Sachdev   +5 more
doaj   +1 more source

Circulating Free RNA as a Therapeutic Evaluation in Diffuse Large B-cell Lymphoma: A Case Series from the Indonesian Cancer Center

Acta Medica Indonesiana
Cancer is still the leading cause of death worldwide. Despite advances in diagnosis, management with the rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) chemotherapy regimen, and careful clinical and ...
Noorwati Sutandyo, Ikhwan Rinaldi, Lyana Setiawan, Christine Sugiarto, Yuniar Harris Prayitno   +4 more
doaj  

Zanubrutinib monotherapy in CD79B‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study

HemaSphere, Volume 10, Issue 10, October 2026.
Li Wang, Keshu Zhou, Fei Li, Qingyuan Zhang, Hui Zhou, Ou Bai, Liping Su, Chunhong Hu, Zhi‐Ming Li, Kaiyang Ding, Qunyi Guo, Xiaoling Li, Xiaoxi Zhou, Wenjuan Yu, Shuhua Yi, Zhixia Wei, Wenbin Qian, Feiheng Chen, Guohui Cui, Zhiyu Liang, Qingchao Zeng, Jiaoyan Lyu, Yang Liu, Pan Zhang, Zhirong Shen, Zaixing Shi, Jing Rong, Wei‐Li Zhao   +27 more
wiley   +1 more source

Advances in γδ T Cells: Cutaneous Biology and Therapeutic Potential for Skin Neoplasms

The Journal of Dermatology, Volume 53, Issue 10, Page 1415-1428, October 2026.
ABSTRACT γδ T cells represent an increasingly important subset of T lymphocytes in the immune response to cancer and as a platform for novel immunotherapies. The aim of this review is to synthesize recent insights into the biology and advances in therapeutic applications of γδ T cells in cutaneous malignancies, especially melanoma, within a framework ...
Simo Du, Anika Jallorina, Toru Yoshino, Lingyu Bao, Han Bao, Victor Chang, Henry K. Wong, Derek V. Chan, Stephen K. Richardson, Mary F. Lee‐Wong   +9 more
wiley   +1 more source

DLBCL Coast to Coast

HemaSphere, 2018
openaire   +3 more sources

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

British Journal of Haematology, Volume 209, Issue 4, Page 1651-1663, October 2026.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend, Nilanjan Ghosh, Martin Hutchings, Michael Dickinson, Monica Tani, Armando Santoro, Michael Crump, Amitkumar Mehta, Reinhard Marks, Martin Weisser, Martin Barrett, Chun Wu, Derrick Kaufman, Katharina Lechner, Pauline Baumlin, Pontus Lundberg, Max S. Topp   +16 more
wiley   +1 more source

Harnessing Quantitative Medicine to Advance Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Oncology drug development continues to have a high attrition rate despite major advances in therapeutic modalities such as antibody‐drug conjugates, bispecific antibodies, cell therapies, and cancer vaccines. Critical development decisions are often made under substantial uncertainty, creating a need for quantitative approaches that integrate ...
Benjamin Wu, Kenta Yoshida, Pascal Chanu, Chunze Li   +3 more
wiley   +1 more source

Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape. [PDF]

Biomedicines
Marquet-Palomanes J, Martin-Moro F, Garcia-Vela JA.   +2 more
europepmc   +1 more source

Extranodal Marginal Zone Lymphoma: Integrating Etiology, Microenvironment, and Genetics Into Clinical Decision‐Making

European Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.
ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi, Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Marco Fiorillo, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +15 more
wiley   +1 more source

Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200. [PDF]

Front Oncol
Qi S, Deng L, Luo S, Yao Y, Chen T.
europepmc   +1 more source